Peptide Discovery & Research History
Every peptide in our catalogue started as an answer to a specific research question, often decades before it became something a distributor like KYIN could supply. Some were found by accident while researchers were looking for something else entirely; others were purpose-built to fix a known problem with an earlier compound. This page traces where each one actually came from.
This is historical and educational context only — it says nothing about current regulatory status, safety, or legal standing in any market. See each product page for handling and purity information.
Weight Loss & Metabolic
Semaglutide
Built on 1980s GLP-1 hormone discoveries, Novo Nordisk's semaglutide established the modern incretin drug class.
Read the full history →Tirzepatide
Eli Lilly's unimolecular dual GIP/GLP-1 agonist, first described in 2018 and FDA-approved as Mounjaro and Zepbound.
Read the full history →Retatrutide
Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist, first published in 2022 and still in Phase 3 trials.
Read the full history →AOD-9604
An hGH fragment engineered to isolate fat-metabolizing activity — six human trials, over 900 participants, still fell short.
Read the full history →5-Amino-1MQ
A small-molecule NNMT inhibitor developed at UTMB in 2018 to validate a 2014 genetic obesity-target discovery.
Read the full history →Cagrilintide
Novo Nordisk applied semaglutide's own fatty-acid acylation technology to build this long-acting amylin analog.
Read the full history →GHRH & Growth Hormone
Tesamorelin
Developed for HIV-associated lipodystrophy research and FDA-approved as Egrifta in 2010 — the one peptide here with a named drug approval.
Read the full history →CJC-1295
Developed by ConjuChem in the mid-2000s using "Drug Affinity Complex" technology to extend GHRH's natural half-life from minutes to several days.
Read the full history →Ipamorelin
Novo Nordisk's 1998 answer to unwanted cortisol and prolactin spikes seen with earlier growth-hormone secretagogues.
Read the full history →Sermorelin
The unmodified GHRH(1-29) fragment that CJC-1295 and Tesamorelin's stability modifications were built to improve on.
Read the full history →GHRP-6
Tulane researchers' 1980s secretagogue that helped identify the ghrelin receptor years before ghrelin itself was found.
Read the full history →Healing & Recovery
BPC-157
Traced to a 1975 hypothesis by a University of Zagreb medical student about the stomach's own self-protective compound.
Read the full history →TB-500
A fragment of thymosin beta-4, isolated in 1981, later reframed as a cytoskeletal regulator a decade after its discovery.
Read the full history →KPV
The minimal fragment of alpha-MSH found in 1989 to retain anti-inflammatory activity without pigmentation effects.
Read the full history →GHK-Cu
Discovered in 1973 while researching why young blood plasma made aged liver tissue behave younger.
Read the full history →ARA-290
Engineered from erythropoietin's helix-B region after researchers found EPO's tissue-protective effects work through a separate receptor.
Read the full history →Thymosin Alpha-1
Isolated in 1972 from calf-thymus extract, later developed into the approved drug thymalfasin (Zadaxin).
Read the full history →Both blends combine peptides with the independent research histories described above. See KLOW Blend and TB-500 + BPC-157 Blend for current specifications.
Cognitive & Nootropic
Selank
A Moscow research team's 1990s attempt to stabilize the immune peptide tuftsin — which unexpectedly gained anxiolytic effects instead.
Read the full history →Semax
Created in 1982 using the same stabilization approach applied to a nootropic fragment of ACTH.
Read the full history →Pinealon
Vladimir Khavinson's bioregulator research extended from the pineal gland to the brain itself.
Read the full history →DSIP
Isolated from rabbit cerebral venous blood in 1977 — nearly five decades later, its mechanism remains poorly understood.
Read the full history →Longevity & Cellular Health
Epitalon
Grew out of 1970s Soviet research into short organ-specific regulatory peptides, led by Vladimir Khavinson.
Read the full history →SS-31
Found by accident during opioid-receptor research, when a lead compound turned out to concentrate inside mitochondria.
Read the full history →MOTS-c
Discovered hidden inside mitochondrial DNA by a USC team in 2015 — a discovery that opened up an entirely new research category.
Read the full history →Cartalax
The same Khavinson bioregulator lineage as Epitalon, extended to cartilage tissue — with a considerably thinner evidence base.
Read the full history →NAD+
A basic cellular coenzyme reframed as a longevity target once its well-documented age-related decline was established.
Read the full history →FOXO4-DRI
Engineered to disrupt the FOXO4-p53 interaction senescent cells rely on to evade apoptosis — a senolytic proof of concept.
Read the full history →Sexual Health & Wellness
PT-141
Palatin Technologies' melanocortin analog of Melanotan II, developed into the FDA-approved drug Vyleesi in 2019.
Read the full history →Kisspeptin-10
Discovered in 1996 as a cancer-metastasis suppressor in Hershey, Pennsylvania — its reproductive role was found only later.
Read the full history →Discovery & history questions
Does a peptide's research history mean it's approved for a particular use?
No. This page describes how each compound was originally discovered and what question the original research was investigating — it is historical and educational context, not a claim about current regulatory approval, safety, or legal status anywhere. Every peptide on this page is sold strictly for laboratory research use.
Why do several of these peptides trace back to Soviet or Russian research institutes?
The Institute of Molecular Genetics of the Russian Academy of Sciences, associated with researcher Nikolai Myasoedov, produced a distinct line of short regulatory-peptide research from the 1980s onward, including Semax and Selank. It's a separate research lineage from the Western academic and pharmaceutical programs behind peptides like BPC-157 or Ipamorelin, not a sign that one lineage is more or less credible than another.
How long have peptides been studied in research?
Peptide research spans nearly a century in a general sense — insulin, one of the first therapeutic peptides, was isolated in 1921 — but the specific research peptides in KYIN's catalogue mostly trace back to work beginning in the 1970s through the 1990s. See each compound's discovery history above for its exact date and origin.
Looking for specs and pricing?
Browse the full catalogue for purity, sizes, and pricing on every peptide.